This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herberger, B. Articles by Filipits, M. Search for Related Content PubMed PubMed Citation Articles by Herberger, B. Articles by Filipits, M.

Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma

Authors' Affiliations: Departments of ¹ Medicine I, ² Surgery, and ³ Clinical Pathology, Medical University of Vienna, Vienna, Austria

Requests for reprints: Martin Filipits, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria. Phone: 43-14277-65237; Fax: 43-14277-65196; E-mail: martin.filipits{at}meduniwien.ac.at.

Purpose: The mammalian target of rapamycin (mTOR) is a protein kinase that plays a key role in cellular growth and homeostasis. Because its regulation is frequently altered in tumors, mTOR is currently under investigation as a potential target for anticancer therapy. The purpose of our study was to determine the prognostic value of activated mTOR (p-mTOR) in patients with biliary tract adenocarcinoma (BTA), in order to strengthen the rationale for targeted therapy of BTA using mTOR inhibitors.

Experimental Design: We determined expression of p-mTOR in paraffin-embedded surgical specimens of BTA by immunohistochemistry with a monoclonal antibody to phosphorylated mTOR. Overall survival was analyzed with a Cox model adjusted for clinical and pathologic factors.

Results: Immunostaining for p-mTOR was positive in 56 of 88 (64%) tumors. Activated mTOR was not associated with any of the clinical or pathologic variables of the patients but predicted overall survival of the patients. Overall survival was significantly shorter in patients with p-mTOR–positive tumors as compared with patients with p-mTOR–negative tumors (hazard ratio for death 2.57; 95% confidence interval, 1.35-4.89; P = 0.004). Multivariate Cox proportional hazards regression analyses identified p-mTOR to be an independent prognostic factor for death (adjusted hazard ratio for death, 2.44; 95% confidence interval, 1.24-4.80; P = 0.01).

Conclusions: Patients with BTA and p-mTOR–positive tumors have a significantly shorter overall survival than patients with p-mTOR–negative tumors and may benefit from targeted therapy with mTOR inhibitors in the future.

This article has been cited by other articles:

				B. Herberger, W. Berger, H. Puhalla, K. Schmid, S. Novak, A. Brandstetter, C. Pirker, T. Gruenberger, and M. Filipits Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells Mol. Cancer Ther., June 1, 2009; 8(6): 1547 - 1556. [Abstract] [Full Text] [PDF]

				J.-Y. Chung, S.-M. Hong, B. Y. Choi, H. Cho, E. Yu, and S. M. Hewitt The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma Clin. Cancer Res., January 15, 2009; 15(2): 660 - 667. [Abstract] [Full Text] [PDF]

				S. M. Wilson, D. Barbone, T.-M. Yang, D. M. Jablons, R. Bueno, D. J. Sugarbaker, S. L. Nishimura, G. J. Gordon, and V. C. Broaddus mTOR Mediates Survival Signals in Malignant Mesothelioma Grown as Tumor Fragment Spheroids Am. J. Respir. Cell Mol. Biol., November 1, 2008; 39(5): 576 - 583. [Abstract] [Full Text] [PDF]

				J Boone, F J W T. Kate, G J A Offerhaus, P J van Diest, I H M B. Rinkes, and R van Hillegersberg mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J. Clin. Pathol., August 1, 2008; 61(8): 909 - 913. [Abstract] [Full Text] [PDF]